{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:54:25Z","timestamp":1792619665426,"version":"4.5.0"},"reference-count":10,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,12]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient\u2019s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4\u00d710<jats:sup>9<\/jats:sup>, 2.0\u00d710<jats:sup>9<\/jats:sup>, and 8.0\u00d710<jats:sup>9<\/jats:sup> T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to &lt;0.01\u2009\u00b5g\/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12.<\/jats:p>","DOI":"10.1136\/jitc-2022-005847","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:05:28Z","timestamp":1673345128000},"page":"e005847","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer"],"prefix":"10.1136","volume":"11","author":[{"given":"Julia","family":"Karbach","sequence":"first","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Kiselicki","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brand","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wahle","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgueni","family":"Sinelnikov","sequence":"additional","affiliation":[{"name":"Zellwerk GmbH, Oberkr\u00e4mer, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Gustavus","sequence":"additional","affiliation":[{"name":"Zellwerk GmbH, Oberkr\u00e4mer, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoffmeister","sequence":"additional","affiliation":[{"name":"Zellwerk GmbH, Oberkr\u00e4mer, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Bernd","family":"Prisack","sequence":"additional","affiliation":[{"name":"NextGen Oncology, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Atmaca","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2025100301470427000_11.1.e005847.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052569","article-title":"Immunotherapy in advanced prostate Cancer\u2014Light at the end of the tunnel?","volume":"23","author":"von Amsberg","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025100301470427000_11.1.e005847.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8"},{"key":"2025100301470427000_11.1.e005847.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"2025100301470427000_11.1.e005847.4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41591-022-01742-1","article-title":"Car T cells reach clinical milestone in prostate cancer","volume":"28","author":"Tschernia","year":"2022","journal-title":"Nat Med"},{"key":"2025100301470427000_11.1.e005847.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(06)95001-5"},{"key":"2025100301470427000_11.1.e005847.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"2025100301470427000_11.1.e005847.7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6"},{"key":"2025100301470427000_11.1.e005847.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110814108"},{"key":"2025100301470427000_11.1.e005847.9","doi-asserted-by":"crossref","first-page":"108456","DOI":"10.1016\/j.clim.2020.108456","article-title":"Generation of high-affinity CMV-specific T cells for adoptive immunotherapy using IL-2, IL-15, and IL-21","volume":"217","author":"Luo","year":"2020","journal-title":"Clinical Immunology"},{"key":"2025100301470427000_11.1.e005847.10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fbioe.2019.00194","article-title":"Mass production of highly active NK cells for cancer immunotherapy in a GMP conform perfusion bioreactor","volume":"7","author":"Br\u00f6ker","year":"2019","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:47:13Z","timestamp":1759481233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-005847"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005847","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}